Healthcare groups and tech firms debate FDA evidence requirements for generative AI medical devices

Healthcare stakeholders are questioning how much clinical evidence the FDA should demand before clearing generative AI-enabled medical devices. The debate centers on balancing innovation speed with patient safety.

Industry lobbying groups and technology companies have voiced differing views, with some urging a lower evidentiary bar to accelerate market entry, while others call for rigorous data to ensure reliability.

The FDA has not yet issued definitive guidance, leaving the standards for these emerging tools unsettled and prompting ongoing discussion among regulators and the broader health-care community.